Community-Acquired Infections: Clinical Trials

354 trials for Community-Acquired Infections, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

173 completed, 60 unknown, 36 recruiting, 31 not yet recruiting. 92 Not applicable, 62 Phase 3, 35 Phase 4, 30 Phase 2, 12 Phase 1.

By phase and status

PhaseTrialsStatus
Not applicable92Completed 47, Unknown 12, Not yet recruiting 10, Recruiting 8, Terminated 8, Withdrawn 6, Active not recruiting 1
Phase 362Completed 33, Recruiting 11, Not yet recruiting 5, Terminated 4, Unknown 4, Withdrawn 3, Active not recruiting 2
Phase 435Completed 16, Unknown 9, Recruiting 3, Terminated 3, Not yet recruiting 2, Withdrawn 2
Phase 230Completed 14, Terminated 4, Not yet recruiting 3, Withdrawn 3, Active not recruiting 2, Recruiting 2, Unknown 2
Phase 112Completed 5, Terminated 5, Not yet recruiting 2
Early Phase 13Completed 2, Not yet recruiting 1

Follow Community-Acquired Infections: new trials by email Literature Review of Community-Acquired Infections trials Research Report on Community-Acquired Infections

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia
Ceftriaxone 1 gram daily, Ceftriaxone 2 grams daily - Community Acquired Pneumonia (CAP)
Phase 4Not yet recruitingUniversity of Maryland, Baltimore9002027-02-012026-11-05
Multimodal Stewardship Programme to Improve Antibiotic Prescribing for Children With Lower Respiratory Tract Infections
PRACTICE-LRTI multimodal antimicrobial stewardship programme - Bronchitis, Acute, Community-acquired Pneumonia
Not applicableNot yet recruitingTampere University500002027-01-012026-11-03
Traditional Chinese Medicine in Multidrug-Resistant Bacterial Pneumonia
Multi Drug Resistant Infections, Pneumnia
Not yet recruitingHenan University of Traditional Chinese Medicine6522026-12-012026-10-30
FIA Acute Inflammation
⁵⁷Fe-labelled ferrous sulphate, ⁵⁸Fe-citrate - Inflammation, Iron Absorption
Not applicableNot yet recruitingUniversity of Zurich482026-11-092026-11-12
Antibiotic Therapy In Respiratory Tract Infections
Predetermined treatment duration, Variable treatment duration - Community-Acquired Pneumonia
Not applicableNot yet recruitingAssistance Publique - Hôpitaux de Paris3102026-11-012026-11-12
Inhaled Lexofloxacin vs Usual Care for Treatment of Community-Acquired Pneumonia
Inhaled levofloxacin, Standard-of-care / Usual care - Community-acquired Pneumonia, CAP
Phase 2 / Phase 3Active not recruitingCopenhagen Respiratory Research4602026-10-082026-11-05
CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL
Placebo, clarithromycin - Sepsis
Phase 3RecruitingHellenic Institute for the Study of Sepsis2522026-09-162026-11-03
TCM Cohort for Elderly CAP
Traditional Chinese medicine (TCM), Non-traditional Chinese medicine (non-TCM) - Community-acquired Pneumonia (CAP)
Not yet recruitingHenan University of Traditional Chinese Medicine22342026-08-202026-09-01
Lefamulin Post-Market Surveillance Study
This is a multicenter, single-arm, non-interventional study. No interventional measures will be adopted. - Community-Acquired Pneumonia (CAP)
RecruitingMarubeni Pharmaceuticals (Suzhou) Co., Ltd.10002026-06-302026-08-07
3 vs. 5 Days of Amoxicillin for Childhood Pneumonia: An RCT
Amoxicillin - Community Acquired Pneumonia, Childhood Pneumonia
Early Phase 1Not yet recruitingKhyber Teaching Hospital2502026-06-012026-06-15
Multicenter Phase II Trial of NRICM102 Combined With Standard Therapy in Pneumonia
NRICM102, Placebo, Intravenous Antibiotic - Mild to Moderate, Community-Acquired Pneumonia (CAP)
Phase 2Not yet recruitingNational Research Institute of Chinese Medicine, Ministry of Health and Welfare1502026-06-012026-05-13
Multimodal Assisted Diagnosis for Pediatric Respiratory Diseases Using Questionnaires, Cough Sounds, and Breath Sounds
Multimodal respiratory data collection - Asthma (Diagnosis), Community-Acquired Pneumonia (CAP)
Not yet recruitingShanghai Children's Medical Center14002026-06-012026-05-29
Community-acquired Pneumonia Due to Chlamydia Pneumoniae
Community-Acquired Pneumonia
Not yet recruitingCentre Hospitalier de Saint-Denis2002026-06-012026-07-01
PromotIng Optimal Treatment for Community-acquired PNeumonia in EmErgency Rooms
The novel care pathway intervention, Usual Care Alone - Community-Acquired Pneumonia (CAP), Pneumonia
Not applicableRecruitingJeffrey Pernica6982026-04-152026-04-29
Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia
Nogapendekin alfa inbakicept (NAI), agenT-797 - Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS)
Phase 3WithdrawnImmunityBio, Inc.2026-04-152026-05-08
Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)
Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797) - Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum
Phase 2WithdrawnImmunityBio, Inc.2026-04-152026-05-08
Effect of tNGS on CAP Patients With Initial Treatment Failure
Targeted next-generation sequencing, Conventional microbiological testing, Follow-up at Day 30 - Community Acquired Pneumonia (CAP)
Not applicableNot yet recruitingCapital Medical University5242026-04-102026-03-16
Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia
Icosapent Ethyl 1000 MG Oral Capsule [Vascepa], Placebo - Inflammation, Community Acquired Pneumonia (CAP)
Phase 3RecruitingOttawa Heart Institute Research Corporation1682026-04-082026-05-11
Comparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP)
Methylprednisolone (drug), hydrocortisone - Community Acquired Pneumonia (CAP)
Phase 4RecruitingCopenhagen Respiratory Research16002026-03-102026-03-18
Early Inflammatory-Immune Stratification and Precision Glucocorticoid Intervention in Acute Respiratory Failure Induced by Community-Acquired Pneumonia
Methylprednisolone - Acute Respiratory Failure, Community-Acquired Pneumonia
Phase 1 / Phase 2Not yet recruitingQingyuan Zhan5002026-02-012026-01-22

Showing 20 of 354. Sign in to see all of them.

Narrower conditions

Community-Acquired Pneumonia (324)  ·  Pneumonia (97)  ·  Pneumonia, Bacterial (23)  ·  Sepsis (21)  ·  Respiratory Tract Infections (20)  ·  Healthcare-Associated Pneumonia (19)  ·  COVID-19 (11)  ·  Infections (10)  ·  Bronchitis (9)  ·  Pulmonary Disease, Chronic Obstructive (9)  ·  Respiratory Distress Syndrome (9)  ·  Cross Infection (7)  ·  Bacterial Infections (6)  ·  Disease (6)

Broader conditions

Infections (344)  ·  Respiratory Tract Diseases (328)  ·  Respiratory Tract Infections (313)  ·  Pneumonia (233)  ·  Lung Diseases (147)  ·  Pathological Conditions, Signs and Symptoms (87)  ·  Pathologic Processes (82)  ·  Bacterial Infections and Mycoses (51)  ·  Disease Attributes (50)  ·  Bacterial Infections (41)  ·  Inflammation (27)  ·  Iatrogenic Disease (25)  ·  Virus Diseases (23)  ·  Systemic Inflammatory Response Syndrome (21)

Interventions

Levofloxacin (17)  ·  Moxifloxacin (14)  ·  Ceftriaxone (13)  ·  Amoxicillin (12)  ·  Amoxicillin-Potassium Clavulanate Combination (12)  ·  Azithromycin (10)  ·  Sodium Chloride (9)  ·  Clarithromycin (7)  ·  Methylprednisolone (7)  ·  Ceftaroline (6)  ·  Blood Specimen Collection (5)  ·  Injections (4)  ·  Saline Solution (4)  ·  Tigecycline (4)  ·  nemonoxacin (4)

Sponsors

Pfizer (14)  ·  Assistance Publique - Hôpitaux de Paris (6)  ·  Capital Medical University (6)  ·  GlaxoSmithKline (6)  ·  Henan University of Traditional Chinese Medicine (6)  ·  Qingyuan Zhan (6)  ·  Assiut University (5)  ·  Bayer (5)  ·  Hellenic Institute for the Study of Sepsis (5)  ·  UMC Utrecht (5)  ·  Wyeth is now a wholly owned subsidiary of Pfizer (5)  ·  Biotest (4)  ·  Forest Laboratories (4)  ·  Nordsjaellands Hospital (4)  ·  TaiGen Biotechnology Co., Ltd. (4)

Countries

United States (59)  ·  France (42)  ·  China (36)  ·  Spain (35)  ·  Germany (26)  ·  Italy (18)  ·  Canada (17)  ·  Netherlands (17)  ·  Denmark (16)  ·  Russia (16)  ·  Brazil (15)  ·  Greece (14)  ·  Switzerland (14)  ·  Argentina (13)  ·  Hungary (13)

Top investigators

Adam Hloska, M.D. (2)  ·  Bin Cao, MD (2)  ·  Birgitte Lindegaard, MD, PhD (2)  ·  Christian Backer Mogensen (2)  ·  Francesco Violi, MD (2)  ·  Giulio DiDiodato, MD (2)  ·  Grit Barten-Neiner (2)  ·  Jeffrey Pernica, MD (2)  ·  Jiansheng Li, Doctor (2)  ·  Luis Felipe Reyes, MD, MSc, PhD (2)

Results publications

PMID 12955634, PMID 18508226, PMID 21482570, PMID 23357290, PMID 23578215, PMID 24106842, PMID 24551881, PMID 25487791, PMID 26702925, PMID 30597021, PMID 32919458, PMID 33394942, PMID 33395094, PMID 33964925, PMID 34473343, PMID 34922058, PMID 37489818, PMID 11434826, PMID 11785851, PMID 12038946, PMID 12039881, PMID 12728147, PMID 12806235, PMID 12955635, PMID 14625336, PMID 15293621, PMID 15546111, PMID 15555836, PMID 15561835, PMID 15993671, PMID 16236878, PMID 16537882, PMID 16603606, PMID 16669925, PMID 16763247, PMID 17006405, PMID 17090560, PMID 17278083, PMID 17765048, PMID 17766633, PMID 17901791, PMID 18096708, PMID 18245147, PMID 18328306, PMID 18419482, PMID 18490403, PMID 18566081, PMID 18624669, PMID 18990531, PMID 19036670

NIH funding

2019 (4), 2023 (4), 2015 (2), 2018 (2), 2009 (1), 2014 (1), 2025 (1), R01AI143910 (1), R01GM101197 (1), R61HL183016 (1), U01AI066569 (1)